This article is policy analysis and general information only. It is not medical, legal, or pharmaceutical advice. Compounding regulation in Australia is subject to ongoing TGA, Pharmacy Board, and state regulator activity — always verify current guidance with the relevant authority before relying on any specific point.

Compounding Pharmacy Regulation in Australia: The TGA, GLP-1 Shortages, and the Policy Tension

For most of the past two decades, pharmacy compounding sat quietly at the edge of the Australian therapeutic goods system — a useful but niche activity, mostly limited to paediatric suspensions, hormone preparations for which no commercial product existed at the right dose, and topical formulations for individual patients with specific allergies or sensitivities. It was a small enough corner of pharmacy practice that it rarely attracted sustained media or political attention.

That has changed. Between 2023 and 2026, three converging pressures pushed compounding into the centre of a national health-policy debate. The Therapeutic Goods Administration (TGA) issued repeated supply-shortage notices for branded semaglutide products, opening the door to Section 19A approvals and to a parallel surge in compounded GLP-1 prescribing (TGA, 2024). The March 2025 rescheduling of BPC-157 and TB-500 to Schedule 4 dragged peptide compounding into the prescription-only framework almost overnight (TGA, 2025). And the Pharmacy Board of Australia issued an unusual run of public statements and notifications about practitioner conduct in the compounded-injectable space (Pharmacy Board of Australia, 2025).

This article walks through how Australia actually regulates compounding, where the legal pathways and grey zones sit, what the GLP-1 shortage exposed, what BPC-157 changed for compounders, and where TGA reform appears to be heading.

1. What pharmacy compounding actually is

Compounding is the preparation of a medicine for a specific patient — or, in some defined circumstances, a small cohort — by a pharmacist, in response to a prescription or to meet a clinical need that cannot be met by a commercially available, TGA-registered product.

It is not manufacturing in the regulatory sense. A manufacturer of therapeutic goods in Australia must hold a TGA manufacturing licence, comply with the Code of Good Manufacturing Practice (GMP), and supply products that are entered on the Australian Register of Therapeutic Goods (ARTG). A compounding pharmacist operates under a much narrower exemption, with the trade-off that what they make cannot be marketed, advertised, held in commercial inventory for general supply, or represented as therapeutically equivalent to an ARTG-listed product.

Within compounding itself, several distinctions matter for the policy debate:

• Extemporaneous compounding — a one-off preparation, made on receipt of an individual prescription, for a named patient. Long-accepted as core pharmacy practice.
• Bulk or anticipatory compounding — preparing batches in advance, usually for repeat patients or for clinics that prescribe a formulation regularly. This is where regulatory pressure tends to concentrate, because it begins to resemble small-scale manufacturing.
• Non-sterile compounding — oral suspensions, capsules, topical creams. Lower risk profile.
• Sterile compounding — injectables, ophthalmics, infusions. Substantially higher risk because contamination, endotoxin, or dose-accuracy failures can cause serious harm and cannot be "tasted" or visually screened by the patient.

The GLP-1 and peptide debates almost entirely concern sterile injectable compounding. That is what makes them sensitive in a way that, say, compounding a paediatric phenobarbitone suspension is not.

2. How Australia regulates compounding

There is no single "Compounding Act" in Australia. Regulation is distributed across at least four layers, and that distribution is itself part of the current policy problem.

Therapeutic Goods Administration. The TGA regulates therapeutic goods at the Commonwealth level. Compounding sits inside a manufacturing exemption under the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations — broadly, a pharmacist compounding for an individual patient on prescription is not "manufacturing" therapeutic goods for the purposes of the Act, and therefore does not require GMP licensing. The exemption is conditional. It applies to genuine extemporaneous practice, not to disguised manufacturing.

Pharmacy Board of Australia. Operating under the Australian Health Practitioner Regulation Agency (AHPRA), the Pharmacy Board sets professional practice standards. Its Guidelines on compounding of medicines set out expectations on scope, competence, facilities, documentation, and — critically — the principle that compounding should not be undertaken where a suitable commercial product is available, and should not occur on a scale or in a way that is "essentially manufacturing" (Pharmacy Board of Australia, 2015; updated guidance, 2025).

State and territory pharmacy regulators. Pharmacy premises, pharmacist registration logistics, and inspection regimes sit with state authorities (for example, the NSW Pharmacy Council, the Pharmacy Regulation Authority of South Australia). They handle premises inspections, including the physical facilities needed for sterile compounding (clean rooms, laminar flow hoods, environmental monitoring).

Poisons Standard. Whatever a pharmacist is compounding has to be a substance the prescriber can legally prescribe and the pharmacist can legally handle. The Standard for the Uniform Scheduling of Medicines and Poisons determines whether the active is Schedule 4 (Prescription Only), Schedule 8 (Controlled), or otherwise restricted.

The result is a system that, on paper, has plenty of regulators — but no single one of them has clear, comprehensive, real-time oversight of what is actually being compounded, in what volumes, for which conditions, across the country.

3. Section 19A and the supply-shortage pathway

Section 19A of the Therapeutic Goods Act allows the TGA to approve the import and supply of an overseas-registered equivalent of an Australian-registered medicine when the Australian product is in shortage. It is the legal mechanism that lets, for example, an unregistered US- or EU-labelled product be brought in during a domestic stock-out.

Section 19A is not a compounding pathway. It is an import pathway. But the two intersect, because TGA shortage notices function as a signal — to pharmacists, to prescribers, and to patients — that demand cannot be met through the ordinary registered-supply channel. Once that signal is in the system, several things happen at once:

• prescribers begin seeking alternatives;
• the TGA may issue Section 19A approvals for overseas-sourced product;
• the Pharmacy Board's "no suitable commercial product available" trigger for compounding becomes arguable in a way it normally is not; and
• compounding pharmacies receive a sharp increase in inbound prescriber and patient enquiries.

That is the bridge by which the 2023–2025 semaglutide shortage opened a parallel compounded-GLP-1 market — not because Section 19A authorised compounding, but because the shortage created the regulatory and clinical conditions under which compounding could be framed as filling an access gap.

4. The compounded semaglutide and tirzepatide story, 2024–2026

The TGA's branded semaglutide shortage notices, initially issued during 2022 and extended repeatedly through 2024, sent demand into adjacent supply channels. Compounded semaglutide — and, separately, compounded tirzepatide once that molecule's profile rose — became widely advertised by some Australian clinics and telehealth-aligned prescribers.

Three regulatory tensions surfaced almost immediately:

Advertising. Schedule 4 substances cannot be advertised to consumers in Australia. Direct or indirect promotion of compounded semaglutide to the public — including through social media, influencer content, and clinic websites — sat squarely against existing therapeutic goods advertising rules, regardless of whether the substance was branded or compounded (TGA, 2024).

Equivalence claims. Some compounded preparations were marketed, explicitly or implicitly, as equivalent or comparable to registered semaglutide products. The TGA's position has been that a compounded preparation is, by definition, not therapeutically equivalent to a registered product unless that equivalence has been demonstrated through the data and process that ARTG registration requires — which is precisely what compounding avoids.

Bioequivalence and formulation integrity. A registered GLP-1 product is supplied with characterised pharmacokinetics, a known excipient profile, a validated injection device, and stability data. A compounded version — even using the same active pharmaceutical ingredient — does not automatically carry any of those guarantees. The compounder is responsible for sterility, dose accuracy, container-closure integrity, and stability, but does not run the formal bioequivalence studies that underpin a registered claim.

By late 2025, the TGA had moved from general advisories to specific cease-and-desist actions against named entities marketing compounded GLP-1 products in ways that breached advertising rules or that strayed beyond legitimate compounding (TGA, 2025). The Pharmacy Board issued parallel communications reminding pharmacists that the compounding exemption is for individual-patient need, not commercial substitution for unavailable registered products (Pharmacy Board of Australia, 2025).

The compounded GLP-1 episode did not produce a single high-profile patient-harm event of the kind that drives statutory reform. What it did produce was a sustained demonstration that the existing rules — written for a smaller, quieter compounding sector — were under-resourced for the volume and visibility the sector had acquired.

5. BPC-157, Schedule 4, and what changed for compounders

In March 2025, the TGA rescheduled BPC-157 and TB-500 from unscheduled to Schedule 4 — Prescription Only Medicine. Before that decision, both peptides occupied an ambiguous space: not approved therapeutic goods, not on the Poisons Standard, and supplied widely in "research use only" channels (TGA, 2025).

The reclassification had three effects that mattered for compounding policy:

1. It made compounded BPC-157 and TB-500 lawful to supply only on a valid Schedule 4 prescription, with all the documentation and Authorised Prescriber or Special Access Scheme requirements that attach to unapproved therapeutic goods.
2. It pushed peptide supply that had previously sat outside pharmacy entirely — research suppliers, online channels, unregulated clinics — toward compounding pharmacies, the only domestic channel that could plausibly serve prescribed demand.
3. It exposed compounders to higher regulatory scrutiny on a category — injectable peptides — where the sterile-injectable risk profile is significant and where commercial registered products do not exist for comparison.

For policymakers, BPC-157 is a useful case study because it illustrates how rescheduling decisions reverberate beyond their immediate target. A move intended to bring a substance under prescribing discipline also reshapes the compounding sector that becomes the channel of supply. Our explainer on the BPC-157 rescheduling examines that change in detail, and our broader analysis of TGA peptide regulation places it in the longer arc of peptide policy in Australia.

6. The patient-access argument, and its counterweight

The most coherent argument for a permissive compounding posture is patient access. It has several strands:

• PBS gaps. Many of the medicines now driving compounded demand — GLP-1 agonists for obesity, peptides for musculoskeletal recovery — are either unsubsidised on the PBS or subsidised only within tight indications. Commercial private-script prices can place them out of reach for low- and middle-income patients.
• Cost differentials. Compounded preparations can be priced significantly below private-script registered products, especially where compounders are not paying for branded device assemblies and proprietary excipients.
• Regional access. Patients outside metropolitan centres often face thinner specialist networks and longer supply chains; compounding pharmacies have been a route to maintaining therapy during local stock-outs.
• Clinically reasonable individualisation. There are genuine cases — paediatric dosing, allergy avoidance, end-of-life palliative formulations — where no commercial product fits and compounding is the only realistic answer.

The counterweight is risk, and it concentrates almost entirely in sterile injectables:

• Sterility risk. Contamination of an injectable can cause sepsis, endocarditis, or worse. Sterility failures in sterile compounding have been the source of the most serious overseas compounding incidents.
• Dose-accuracy risk. Subcutaneous peptides and GLP-1 agonists are active at microgram-to-milligram quantities. Small errors in concentration or fill volume translate directly into clinical effect.
• No bioequivalence data. Compounded equivalents of registered products are not, in regulatory terms, the same drug, even when the API is identical. Excipient choice, pH, tonicity, and container interactions all influence pharmacokinetics and tolerability.
• No post-market surveillance. Adverse events linked to compounded preparations are harder to detect, attribute, and act on than those tied to ARTG-listed products with sponsor reporting obligations.

These are not arguments that point cleanly in one policy direction. They are arguments that point toward proportionality — different rules for sterile versus non-sterile, for bulk versus extemporaneous, for individualised need versus volume substitution.

7. International parallels

Australia is not regulating compounding in isolation, and two overseas frameworks tend to be cited in policy discussions here.

United States — FDA 503A and 503B. The US Federal Food, Drug, and Cosmetic Act distinguishes between traditional compounding pharmacies (503A), which compound for individual patients on prescription and operate primarily under state pharmacy law, and "outsourcing facilities" (503B), which can compound in larger volumes for office use, register with the FDA, and submit to FDA inspection and adverse event reporting. The 503B category exists in part because of the 2012 New England Compounding Center contamination incident, which caused a multistate fungal meningitis outbreak and reframed US policy thinking about sterile compounding risk at scale.

United Kingdom — MHRA "specials". UK law recognises "specials" — unlicensed medicines manufactured under a Manufacturer's Specials Licence (MS) to meet the needs of an individual patient. The framework distinguishes between pharmacy-prepared extemporaneous compounding and specials-licensed manufacture, with the latter subject to GMP-style oversight.

Both jurisdictions have arrived, in different ways, at a tiered system in which higher-volume or higher-risk compounding attracts higher-tier regulation. Australia's current framework — a single manufacturing exemption with overlay from Pharmacy Board guidelines and state inspection — does not have that gradation in any formal sense. Whether it should is one of the open questions for TGA reform.

8. Where TGA reform is heading

There are several signals in the public record that point toward a more structured Australian response in 2026–2027:

• The TGA has flagged interest in reviewing the boundaries of the manufacturing exemption, particularly for sterile injectable compounding, in its broader regulatory horizon-scanning documents (TGA, 2025).
• The Pharmacy Board of Australia has revised its compounding guidance and signalled continued focus on bulk and sterile compounding practices (Pharmacy Board of Australia, 2025).
• The Pharmaceutical Society of Australia has called for clearer national standards on sterile compounding facilities and on the boundary between compounding and small-scale manufacturing (Pharmaceutical Society of Australia, 2025).
• Parliamentary and Senate committee attention to GLP-1 access, obesity pharmacotherapy, and pharmacy scope-of-practice has put compounding in proximity to several adjacent reform agendas, including the broader GLP-1 shortage policy debate and the scope-of-practice questions facing community pharmacy.

What an Australian 503B-style tier would look like is unsettled. It might involve a formal registration scheme for sterile-injectable compounders, mandatory adverse-event reporting, defined volume thresholds, or a separate facility-licensing regime. None of these have been formally proposed in legislative form at the time of writing. But the trajectory of TGA, Pharmacy Board, and PSA statements through 2024 and 2025 suggests the policy conversation is moving in that direction rather than away from it.

9. Key takeaways for policymakers

• Compounding has shifted from a niche pharmacy activity to a national policy issue, driven by GLP-1 shortages, peptide rescheduling, and changes in patient demand patterns.
• The legal architecture — a Commonwealth manufacturing exemption, Pharmacy Board professional standards, state premises inspection, Poisons Standard scheduling — was designed for a smaller, quieter sector. It is under strain.
• The GLP-1 compounding episode is best understood not as a regulatory failure in a narrow sense but as a stress test that revealed weak signal-to-action loops between shortage notices, advertising compliance, and Pharmacy Board enforcement.
• BPC-157's reclassification demonstrates how rescheduling reshapes the compounding sector even when compounding is not the direct policy target.
• Sterile injectable compounding deserves a distinct regulatory tier. The strongest case for reform is not about restricting compounding overall but about matching oversight to risk.
• International frameworks (US 503A/503B; UK specials) offer ready models for tiered regulation without abolishing the patient-access value of traditional compounding.
• Patient-access arguments are real and should not be dismissed. They are also strongest where compounding solves an irreducible individualisation problem and weakest where it functions as a parallel commercial supply channel for a product the registered market could in principle serve.

The policy question is no longer whether compounding regulation in Australia needs to evolve. It is whether the evolution will be shaped deliberately — through a transparent, evidence-led process involving the TGA, AHPRA, the Pharmacy Board, professional bodies, consumer voices, and the states — or reactively, after an incident the system was not designed to prevent.

References

• Pharmacy Board of Australia. (2015, updated 2025). Guidelines on compounding of medicines. Australian Health Practitioner Regulation Agency.
• Pharmacy Board of Australia. (2025). Communications and notifications regarding compounded injectable medicines and pharmacist practice obligations.
• Pharmaceutical Society of Australia. (2025). Position statements on sterile compounding standards and pharmacy practice.
• Therapeutic Goods Administration. (2024). Section 19A approvals and shortage notices relating to semaglutide-containing products.
• Therapeutic Goods Administration. (2024). Statements and compliance actions on advertising of compounded prescription medicines.
• Therapeutic Goods Administration. (2025). Final decision on the rescheduling of BPC-157 and TB-500 to Schedule 4 of the Poisons Standard.
• Therapeutic Goods Administration. (2025). Regulatory horizon and reform signalling documents relating to compounding and the manufacturing exemption.
• US Food and Drug Administration. Federal Food, Drug, and Cosmetic Act, sections 503A and 503B.
• Medicines and Healthcare products Regulatory Agency (UK). Guidance on manufacturer "specials" licences and unlicensed medicines.